Reviewer's report
Title:Resveratrol inhibits nonalcoholic fatty liver disease in rats.
Version: 3Date:20 May 2008
Reviewer: Ralf Weiskirchen
Reviewer's report:
Major Compulsory Revisions
The revised version of Bujanda and co-workers addresses most of the points that
I have raised in my initial review. However, the most critical reason why I have
recommended rejection of the manuscript was the failure to demonstrate that the
resveratrol efficiency in reducing NAFLD severity is a direct consequence of
TNF-alpha inhibition. The link was simply postulated but not demonstrated. In the
revised version, the authors have made no experimental attempt to address this
critical issue. In my view it is not sufficient to argue that similar studies in
“prestigious journals” did not include the suggested controls (TNF-alpha blocking
agents or TNF-alpha). Therefore, the major conclusion drawn supposing that the
beneficial effects of resveratrol are a consequence of TNF-alpha inhibition is still
a speculation.
Level of interest: An article of limited interest
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests.
Reviewer's report
Title:Resveratrol inhibits nonalcoholic fatty liver disease in rats.
Version: 3Date:20 May 2008
Reviewer: Ralf Weiskirchen
Reviewer's report:
Major Compulsory Revisions
The revised version of Bujanda and co-workers addresses most of the points that
I have raised in my initial review. However, the most critical reason why I have
recommended rejection of the manuscript was the failure to demonstrate that the
resveratrol efficiency in reducing NAFLD severity is a direct consequence of
TNF-alpha inhibition. The link was simply postulated but not demonstrated. In the
revised version, the authors have made no experimental attempt to address this
critical issue. In my view it is not sufficient to argue that similar studies in
“prestigious journals” did not include the suggested controls (TNF-alpha blocking
agents or TNF-alpha). Therefore, the major conclusion drawn supposing that the
beneficial effects of resveratrol are a consequence of TNF-alpha inhibition is still
a speculation.
Level of interest: An article of limited interest
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests.
Please review this paper.
user
Reviewer's report
Title:Resveratrol inhibits nonalcoholic fatty liver disease in rats.
Version: 3Date:20 May 2008
Reviewer: Ralf Weiskirchen
Reviewer's report:
Major Compulsory Revisions
The revised version of Bujanda and co-workers addresses most of the points that
I have raised in my initial review. However, the most critical reason why I have
recommended rejection of the manuscript was the failure to demonstrate that the
resveratrol efficiency in reducing NAFLD severity is a direct consequence of
TNF-alpha inhibition. The link was simply postulated but not demonstrated. In the
revised version, the authors have made no experimental attempt to address this
critical issue. In my view it is not sufficient to argue that similar studies in
“prestigious journals” did not include the suggested controls (TNF-alpha blocking
agents or TNF-alpha). Therefore, the major conclusion drawn supposing that the
beneficial effects of resveratrol are a consequence of TNF-alpha inhibition is still
a speculation.
Level of interest: An article of limited interest
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests.
assistant